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ABSTRACT 
Objective: To evaluate the reporting of data related to external validity (i.e., applicability of 
the results of a trial in routine practice) from randomized controlled trials (RCTs) assessing 
pharmacologic treatment and nonpharmacologic treatment for hip and knee osteoarthritis. 
Methods: All RCTs assessing pharmacologic treatments (e.g., oral drugs, intra-articular 
injection, topical treatment) and nonpharmacologic treatments  (e.g., surgery, rehabilitation, 
education, joint lavage, nonimplantable devices) for hip and knee osteoarthritis indexed 
between January 2002 and December 2006 were selected. A sample of 120 articles was 
randomly selected, 30 each of trials assessing pharmacologic treatments, surgery or technical 
interventions, rehabilitation and nonimplantable devices.  
Results 
The country where the trial took place was clearly reported in only 21% of reports (n = 25). 
The setting was described in one-third of reports (n = 40) and the number of centres in 45% (n 
= 54). Details of centres (volume of care) were given in 20% of reports (n = 24). Reporting 
rates were lower for surgical trials for the country (3%), the setting (3%), the number of 
centres (13%), and details of centres (volume of care) (7%). The intervention was adequately 
described in all pharmacologic reports and more than 80% of reports of trials assessing 
rehabilitation. In reports of surgical intervention trials, the technical procedure was given in 
all reports, but the type of anaesthesia was reported in 13% (n = 4), pre-operative care in 7% 
(n = 2), and post-operative care in 50% (n = 15). In reports of device trials, the device was 
described in 93%, but the manufacturer was reported in only one-third of the reports. The 
method of recruitment was reported in 36% of reports (n = 43). Eligibility criteria were 
described in most reports (98%), but 22.9% of the exclusion criteria were poorly justified.  
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Conclusion: This study highlights the low reporting lack of data related to external validity in 
reports of RCTs assessing pharmacologic and nonpharmacologic treatments for hip and knee 
osteoarthritis.  
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BACKGROUND 
Well-conducted randomized controlled trials (RCTs) are adopted as the gold standard for 
evaluating medical interventions (1-4). For results to be clinically useful, RCTs must take into 
account the internal validity (i.e., the extent to which systematic errors or bias are avoided) 
and the external validity (sometimes called applicability - i.e., whether the results of a trial 
can be reasonably applied or generalized to a definable group of patients in a particular setting 
in routine practice) (5, 6).  
Historically, internal validity has been considered a priority for research. Several publications 
identified methods to avoid bias(7, 8). The Consolidated Standards of Reporting Trials 
(CONSORT) Statements, endorsed by many major medical journals, improved on the 
reporting of data related to internal validity(1, 9). Tools(10-13) have been developed mainly 
to evaluate internal validity in reports of trial results included in systematic reviews(14). 
 
Funders and journals have tended to be more concerned with the scientific rigor of 
interventions studied than with the applicability of the results. Consequently, external validity 
has been frequently neglected(6, 15-17). This neglect has probably contributed to the failure 
to translate research into clinical practice. Lack of external validity is frequently advocated as 
the reason why interventions found to be effective in clinical trials are underused in clinical 
practice(5). However, assessing the external validity of a trial to turn research into action 
supposes that information is adequately reported in published articles. Further, as highlighted 
by the extension of the CONSORT Statements to nonpharmacologic treatment, assessing 
external validity is probably more difficult for trials assessing nonpharmacologic treatments 
(e.g., surgery, technical interventions, rehabilitation, psychotherapy, devices) than 
pharmacologic treatments (e.g., oral drugs)(18, 19). 
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The aim of this study was to evaluate and compare the reporting of external validity from 
RCTs assessing pharmacologic and  nonpharmacologic treatments for hip and knee 
osteoarthritis (OA). We chose these conditions because they are highly prevalent and can 
result in disability and reduced quality of life. Further, international guidelines require the use 
of a combination of pharmacologic and nonpharmacologic treatments for optimal 
management of patients with these conditions(20, 21). 
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METHODS 
 
Search strategy and selection of reports 
We identified all English-language reports of RCTs indexed between January 2002 and 
December 2006 in PubMed using the search terms “Osteoarthritis Hip” OR “Osteoarthritis 
Knee,” with a limitation to RCTs, in MEDLINE via PubMed and to articles published in 
English. A similar search strategy was used in a previous work on internal validity (22). 
 
Eligibility criteria and screening process  
We collected the electronic records in an Endnote data file. One of us (AN) assessed each 
reports by screening the titles and abstracts to identify relevant studies. A second person (IB) 
checked for adequate selection of the abstracts. Articles were included if the study was 
identified as an RCT assessing pharmacologic or nonpharmacologic treatment for hip or knee 
OA in a parallel-group or cross-over design. We excluded reports of cluster RCTs, 
nonrandomised trials, observational studies (cohort and case-control studies), extended 
follow-up trials (i.e., extended follow-up of patients included in an RCT beyond the last 
outcome assessment), nontherapeutic trials (metrological studies, epidemiological studies), 
pathophysiological studies, letters, an ancillary study of an RCT such as a subgroup analysis, 
cost-effectiveness evaluations, systematic reviews and/or meta-analyses. We also excluded 
reports of trials assessing the organization of the health care system or interventions provided 
to care providers. We excluded reports with these designs because we wanted to have a 
relatively homogeneous sample. 
The selected abstracts were classified according to the category of treatment assessed: 
pharmacologic treatments, surgery or technical interventions (e.g., joint lavage), 
rehabilitation, or nonimplantable devices. 
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For each category of treatment, we used a computer-generated list to randomly select 30 
articles and retrieved the full text articles. Articles not fulfilling the inclusion criteria were 
replaced by a random selection of articles in the corresponding category. We chose a total of 
120 articles for practical reasons, mainly to provide enough articles describing each category 
of treatment, and randomly selected articles to avoid selection bias. 
 
 
Data collection 
To assess external validity, as well as internal validity of the selected reports, we reviewed the 
literature and generated a standardized data extraction form (available upon request); we used 
items related to external validity proposed by the CONSORT Statement for RCTs(1), the 
extension of the CONSORT Statement for nonpharmacologic trials(18, 19) and Rothwell et 
al.(5) Before data extraction, as a calibration exercise, the standardized form was tested 
independently by two members of the team (AN, IB) on a separate set of 20 reports. A 
meeting followed in which the ratings were reviewed and any disagreements were resolved by 
consensus. One reviewer (AN) independently completed all the data extraction. A random 
sample of 20 articles was reviewed for quality assurance.  
 
The data extraction form covered the following data: 
 
1) Characteristics of the selected studies: year of publication, journal, medical area of the 
study (i.e., hip OA, knee OA, hip and knee OA), type of treatment (i.e., pharmacologic 
treatment, surgical intervention, rehabilitation or education, nonimplantable device), type of 
control intervention (i.e., active intervention, placebo, usual care), funding sources (i.e., 
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public, private, both, no funding, not reported or unclear), study design (i.e., parallel-group, 
cross-over) and sample size.  
Internal validity of the selected reports was assessed with use of the following specific criteria 
recommended by the Cochrane collaboration and by most quality tools assessing results of 
pharmacologic and nonpharmacologic trials(10, 12): allocation sequence generation; 
allocation concealment; blinding of patients, care providers and outcome assessors; and 
intent-to-treat (ITT) analysis. 
 
2) External validity 
The reporting of the following data related to external validity was evaluated: 
Recruitment: data on the method of recruitment (i.e., referral from a rheumatologist or general 
physician, self-selection of patients through advertisement) and duration of recruitment.  
 
Patients: data on patients’ eligibility criteria as defined in a previous work (23), inclusion 
criteria (i.e., criteria governing entry or recruitment of individuals into the trial and describing 
the medical conditions of interest) and exclusion criteria (all other criteria limiting the 
eligibility of individuals)(23). The exclusion criteria were classified as strongly justified, 
potentially justified and poorly justified reasons for excluding individuals from an RCT 
according to the classification proposed by Van Spall et al.(23); exclusion criteria were 
considered strongly justified if an individual or substitute decision-maker was unable to grant 
informed consent, the intervention or placebo would likely be harmful, the intervention would 
likely be ineffective, or the effect of the intervention would be difficult to interpret. 
Data on the number of eligible patients, number of patients not meeting inclusion criteria and 
number of patients refusing to participate were collected. We also checked whether the article 
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reported baseline characteristics of excluded patients, as well as essential data on baseline 
characteristics of randomized patients (i.e., age, sex, weight/body mass index, ethnicity, 
coexisting diseases or co-morbidities, duration of the disease, measure of function status, level 
of pain, description of radiographic evidence of damage, and use of nonsteroidal anti-
inflammatory drugs). 
 
Centre and care provider: data on the number of centers/care providers, expertise of 
centers/care providers and details of the centers (name, sources, organization, and expertise). 
The reporting of the number of patients recruited in each center or by each care provider was 
recorded. 
 
Intervention (i.e., whether and how details on the interventions were reported): for 
pharmacologic treatments, the route of administration, dosage, duration, frequency of 
treatment, and patient compliance; for rehabilitation, the number, timing, duration and content 
of each session, mode of delivery, supervision or not, and patient compliance; for surgical 
interventions, the type of anaesthesia, pre-operative care, post-operative care, description of 
the technical procedure and surgeons’ compliance with the planned procedure; and for 
nonimplantable devices, the reporting of the manufacturer, description of the devices and 
patient compliance.  
 
Abstract and discussion sections: information related to external validity reported in the 
abstract (i.e., country where the trial took place, setting, number of centers, number of eligible 
patients, number of patients randomized, length of recruitment, length of follow-up, and data 
on care providers) and whether the external validity was discussed in the discussion section of 
the study as recommended by the CONSORT Statement (1). 
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Global assessment of external validity: quantitative assessment of external validity reporting 
may offer complementary information. Although it is difficult to specify which aspect of 
external validity is the most important, we decided to focus on 3 important components that 
are probably indispensable to assess the external validity of a trial: 1) the participants, 2) the 
description of the experimental treatment, and 3) the context of care (centres, setting, care 
providers’ expertise). For each component, we identified items that were considered essential 
to allow an adequate assessment of the external validity of a published trial. These items are 
described in the box. The quantitative assessment of external validity was evaluated by the 
percentage of the selected items that were adequately reported, for each component. 
 
Statistical analysis 
All data analyses were completed using SAS for Windows, Release 9.1 (SAS Institute, Cary, 
NC). 
We used descriptive statistics for continuous variables: means, standard deviation (SD), 
median (lower quartile; upper quartile) and minimum and maximum values. Categorical 
variables are described with frequencies and percentages. The results were adjusted for the 
clustering effect by journals as recommended (24). The reporting of data related to external 
validity according to category of treatment was compared by a linear mixed-effects model, 
with the percentage of items with external validity as the dependent variable, fixed effects for 
treatment category, and journal as a random effect. 
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RESULTS 
Articles selected 
We identified 388 citations from our electronic search, of which 123 were excluded. Among 
the 265 included reports, we randomly chose 120 reports, 30 for each category of treatment. 
After obtaining and reviewing the full text, 11 articles were replaced. The flow of articles 
through the study is presented in appendix 1.  
 
Characteristics of the selected studies 
Characteristics of the included studies are reported in table 1. The 120 articles were indexed 
in 53 journals. Among them, 13 (11%) were published in a general medical journal with a 
high impact factor and 107 (89%) in a general medical journal with low impact factor or in a 
special medical journal. Most trials, 118 (98%), had a parallel-group design. Three-quarters of 
the reports assessed knee OA (n = 90). The source of funding was described as public in 45 
articles (38%), completely or partially private in 25 (21%). A funding source was not reported 
in 50 reports (42%).  
The median sample size (interquartile range) was 100 (60-216) and was twice as high 
for reports of pharmacologic trials as nonpharmacologic trials. 
The control group was described as receiving active treatment in 63 reports (52%), a 
placebo intervention in 43 (36%) and usual care in 14 (12%). Pharmacologic treatments and 
nonimplantable devices were mainly compared to placebo or active treatments, whereas 
rehabilitation interventions were mainly compared to usual care or active treatments, and 
surgical procedures were compared to active treatment in most reports. 
 The generation of allocation sequences was adequate in 51% of the reports. The 
treatment allocation was adequately concealed in 41% of reports (n = 49). Blinding was 
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reported and was adequate in 43% of reports for patients, 32% for care providers and 59% for 
outcome assessors. An ITT analysis was described in only one-third of the reports.  
 
External validity   
The results for assessing external validity are reported in tables 2 and 3 and figure 1. 
 
Recruitment (table 2) 
The method of recruitment was described in about one-third of the reports; when described, this 
method relied on referral in 67% of reports (n = 29/43) and self-selection in 33% (n =14/43). The 
duration of recruitment was described in 47% of reports (n = 56); reporting was better in articles 
about rehabilitation. The median (interquartile range [IQR]) duration of recruitment for 10 
patients per month described was 0.4 [0.2-0.8] months for pharmacologic trials; 0.8 [0.3-1.9] for 
device trials; 1.2 [0.9-2.7] for rehabilitation trials; and 2.5 [1.1-4.4] for surgical trials. 
 
Participants (table 2) 
Inclusion criteria were described in almost all reports (98%, n = 118) and exclusion criteria in 
88% (n = 106). Exclusion criteria focused on age in 53% of reports (n = 64), medical co-
morbidities in 66% (n = 79), sex in 14% (n = 17), medication in 48% (n = 57), socioeconomic 
status in 2% (n=3), and patients participating in another trial in 5% (n=6).  
Twenty-three percent of reports poorly justified exclusion criteria. These rates did not 
differ by category of treatment. 
A flow diagram of participants through the trial was given in 40% of reports (n = 48). 
Data related to the number of eligible participants, number of participants not meeting 
inclusion criteria and those refusing participation were reported in less than half of the reports, 
but reporting was better for rehabilitation trials. When given, the mean rate of participants not 
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meeting inclusion criteria and refusing to participate was 22.5 (30%) and 19.2 (16%), 
respectively. 
Baseline data of excluded participants were given in only one report. The baseline 
clinical characteristics of randomized participants were described in 91% of reports (n = 109); 
characteristics concerned age and sex in more than 80% of reports, weight or body mass index 
in 62%, and severity of disease (i.e., duration of the disease, pain, function, radiographic 
evidence of damage) in less than half. Patients’ comorbidities were provided in only 12% of 
reports.  
 
Interventions (table 3) 
The treatments were described according to the CONSORT recommendations in all reports of 
pharmacologic trials and in most reports of rehabilitation trials but were missing in reports of 
devices and surgery trials. In the reports of medical device trials, a description of the device 
was given in 93% of reports (n = 28), but the manufacturer was stated in only 30% (n = 9). In 
the reports of surgical intervention trials, the technical procedure was given in all reports, but 
the type of anaesthesia was reported in only 13% (n = 4), pre-operative care in 7% (n = 2), 
and post-operative care in 50% (n = 15). Control treatment was described in most reports 
(98%, n = 117). Descriptions of co-interventions were lacking in 23% of reports (n = 28), 
mainly reports of pharmacologic trials.  
 
Centres and care providers (table 2) 
The setting was described in 33% of reports (n = 40) and the number of centres in 45% (n = 
54). The country where the trial took place was clearly reported in only 21% of reports (n = 
25). Details of centres were given in 20% of reports (n = 24). Other details such as centre 
sources, organization and expertise were never reported. The number of participants recruited 
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in each centre was never reported. Details on care providers were given in 29% of reports (n = 
35). 
 
Abstract and discussion sections 
Information related to external validity was provided in the abstract of reports as follows: 4% 
of articles (n = 5) described the country where the trial took place, 15% (n = 18) the setting, 
12% (n = 14) the number of centres, 2% (n = 2) the number of eligible patients, 92% (n = 
110) the number of patients randomized, 5% (n = 6) the length of recruitment, 82% (n = 98) 
the length of follow-up, and 2% (n = 2) data on care providers. External validity was 
discussed in the discussion section of 11 articles (9%).  
 
Global assessment of external validity (figure 1) 
Figure 1 highlights the reporting of each component of external validity by category of 
treatment. Reporting of essential baseline characteristics items was lower in reports of 
surgical trials, with a median [IQR] of 30% [30-40] of the essential items reported, than for 
those of trials of pharmacologic treatments, nonimplantable devices and rehabilitation, with a 
median [IQR] of 50% [40-60], 50% [30-60] and 45% [30-60], respectively, of the essential 
items reported (p= 0.006).  
The reporting of the intervention was better in reports of trials of pharmacologic 
treatments and rehabilitation (median [IQR] 80% [80-100] and 86% [71-100], respectively) 
than for those of trials of nonimplantable devices and surgery (median [IQR] 33% [33-67] and 
40% [20-40]), respectively; p <0.001).  
The items dedicated to the context of the trial were poorly reported for trials of all 
treatments, especially pharmacologic treatments and surgery (median [IQR] 12% [12-25] and 
25% [12-25]), respectively; p = 0.016).
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DISCUSSION 
 
This study assessed the reporting of external validity in a sample of 120 RCTs assessing 
pharmacologic and nonpharmacologic treatments for hip or knee OA during a 5-year period. 
Our results highlight the lack of data related to external validity in published reports of RCTs. 
Methods for recruiting patients were described in one-third of the reports; 22.9% of the 
exclusion criteria were poorly justified; important baseline data of patients were lacking; and 
setting, centers and care providers were described in one-third and less of articles. Further, the 
reporting of external validity differed depending on the category of treatment. Reports of 
trials assessing rehabilitation provided more adequate data related to recruitment, participants, 
setting and centers, and intervention. On the contrary, reports of trials assessing surgical 
procedures lacked such data, even though the reporting of some items, such as the setting, the 
number of centers and center volume, is particularly important in this field. In reports of 
pharmacologic trials and trials assessing nonimplantable devices, the reporting was of varying 
quality. In reports of pharmacologic trials, the reporting of the method of recruitment and of 
data related to centers and care providers was poor, but the reporting of the intervention was 
good.  
 
To our knowledge, this is the first study that systematically appraised the reporting of data 
related to external validity from trials assessing pharmacologic and  nonpharmacologic 
treatments. Most recent efforts of researchers and editors to improve the reporting of results of 
RCTs, such as the CONSORT initiative, have mainly focused on internal validity (1, 9). 
Nevertheless, external validity is also essential and needs to be emphasized (25, 26). The 
results of RCTs and systematic reviews cannot be relevant to all patients and all settings. 
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Consequently, reporting the results of RCTs should allow clinicians to judge to whom and in 
which context these results could reasonably be applied. 
 
The setting, care providers and centers have obvious implications for external validity(5, 27). 
In fact, the applicability of results of trials performed in secondary or tertiary settings applied 
to primary settings is often a concern (5). Further, differences between health care systems 
can affect the applicability of results, especially regarding organization of care or 
reimbursement for the cost of care(5). These issues are crucial in trials assessing  
nonpharmacologic treatments such as surgery or technical interventions. In fact, hospital and 
care providers’ volume and outcome are related (28-33). A surgical procedure might be found 
to be safe and effective in an RCT performed in high-volume centres by high-volume care 
providers, but applying these results to low-volume centres might result in very different 
results (27, 34, 35). Surprisingly the reporting of data on care providers and centers was far 
less than optimal in our study, especially for trials assessing surgical procedures. 
 
The representativeness of patients included in a RCT is also a major issue for external 
validity. The inclusion and exclusion criteria are among the greatest challenges in achieving 
representativeness of participants. Highly selective eligibility criteria can considerably reduce 
the applicability of the trial results. Our results highlight the lack of reporting of exclusion 
criteria in 12% of the trial reports; 23% of reported exclusion criteria were poorly justified. 
These results are consistent with those of a systematic review of RCTs published in high-
impact-factor journals between 1994 and 2006(23). Exclusion criteria reported in our articles 
concerned mainly elderly patients, those with medical comorbidities or those treated with 
specific categories of treatments. The exclusion of these specific categories of participants is 
problematic because it limits the representativeness of the patients.  
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The representativeness of the participants is also problematic because those agreeing to 
participate in RCTs often differ from those who do not participate. (36-39). Consequently, the 
number of eligible nonrandomized patients, as well as the number of participants who were 
invited to participate but declined, is important to adequately appraise the external validity of 
a trial(22); however, these data were reported in only one-third and one-quarter, respectively, 
of our reports, which is consistent with previous results (40).  
 
Reporting the baseline clinical characteristics of participants included in RCTs should allow 
clinicians and others to assess external validity by comparison with their patients. Although 
baseline characteristics were described in almost all of our reports, some important data were 
missing: weight or body mass index, while essential, was given in only 62% of the selected 
articles. The reporting of ethnicity, comorbidities and severity and activity of the disease 
(pain, function, radiographic evidence of damage), which also predict response to and 
influence the generalisability of treatment was also inadequately reported (41-44).    
 External validity could also be affected if trials have treatment protocols that differ 
from usual clinical practice or have too stringent limitations on the use of cointerventions. 
Further, to be able to adequately apply the results of the trial in clinical practice, the 
treatments should be described in detail to allow for adequate reproducibility. Our results 
highlight the lack of descriptions of nontrial treatments in two-thirds of the reports of 
pharmacologic trials and that descriptions of all the components of nonpharmacologic trials 
were lacking, especially in reports of surgery (45). 
 
Finally, despite a specific item of the CONSORT Statement dedicated to external validity, 
very few articles considered this issue in the discussion section. 
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Our study has several limitations. First, we focused on the reporting of the trial, not its 
conduct. Consequently, these results highlight the lack of adequate reporting of external 
validity criteria and do not provide information on the applicability of the results of the trial. 
Second, the results related to the rate of poorly justified exclusion criteria might be 
underestimated. In fact, some researchers have highlighted the inadequate reporting of 
eligibility criteria when comparing the published article with the protocol(46); among an 
average of 31 eligibility criteria, only 63% were described in the main trial reports. Third, we 
focused on RCTs assessing hip and knee OA, and these results should be confirmed in other 
medical areas. However, we chose this disease because it is frequent and involves a wide 
range of pharmacologic and  nonpharmacologic treatments. Further, the authors had some 
expertise in rheumatology and orthopedics and could therefore adequately evaluate the 
context of the trials. 
 
In conclusion, this study highlights the lack of consideration of external validity in published 
reports of RCTs. Much attention is paid to the internal validity of clinical trials; however, 
even results of well-designed clinical trials are of limited use to clinicians if they have poor 
external validity and are not applicable to the patients for whom the intervention is designed. 
Recently the CONSORT group developed an extension of the CONSORT Statements for 
pragmatic trials. This extension increases the focus on data related to external validity. This 
initiative should help improve the consideration of external validity. 
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 Legend 
 
Box: Components of external validity evaluated in selected reports of trials of 
pharmaceutical and nonpharmaceutical treatments for hip and knee osteoarthritis 
 
Figure 1: Median percentage (interquartile range) of items of components of external 
validity that were reported in selected reports of pharmaceutical and 
nonpharmaceutical treatments for hip and knee osteoarthritis  
Scores are based on the percentage of items of the following components (baseline data, 
intervention, context) that were reported. Boxes represent median observations (horizontal 
rule), with 25th and 75th percentiles of observed data (top and bottom of box). In some 
instances, the median observation coincided with the 25th and 75th percentiles. Error bars 
represent the 10th and 90th percentiles. The cross represents the mean value.  
A) Baseline items: percentage of essential data for the following baseline characteristics 
of randomized patients that were reported: age, sex, weight/body mass index, 
ethnicity, duration of disease, measure of function status, level of pain, description of 
radiographic evidence of damage, use of NSAIDs/other drugs, coexisting diseases.  
B) Interventions: percentage of the following essential items related to the intervention 
for each category of treatment that were reported:  
a. Pharmacologic treatments (PT): route of administration, dosage, duration of 
treatment, frequency of treatment, compliance of patients 
b. Devices: manufacturer, description of the devices, compliance of patients 
c. Surgery: type of anesthesia, pre-operative care, post-operative care, technical 
procedure, compliance of care providers 
d. Rehabilitation: number of sessions, timing of sessions, duration of each 
session, content of each session, mode of delivery, supervision or not of the 
session, compliance of patients 
 C) Context items: percentage of the essential items related to the context that were 
reported: location of recruitment, setting of recruitment, country where the trial took 
place, number of centers, details of the centers (e.g., name, center resources, center 
expertise, center organization), number of patients recruited in each center, details of 
care provider (qualification, name, experience, years of practice), number of care 
providers participating 
 
 
 Box: Components of external validity evaluated in selected reports of trials of pharmacologic 
and nonpharmacologic treatments for hip and knee osteoarthritis 
Description of 
participants 
 
Percentage of the following baseline data reported 
1. Age 
2. Sex 
3. Weight/body mass index 
4. Ethnicity 
5. Duration of disease 
6. Measure of function status  
7. Level of pain 
8. Description of radiographic evidence of damage 
9. NSAIDs/other drugs 
10. Coexisting diseases 
 
Intervention Percentage of the following data describing the intervention reported 
 
Pharmacological Treatment 
1. Route of administration 
2. Dosage  
3. Duration of treatment 
4. Frequency of treatment 
5. Compliance of patients 
 
 Devices 
1. Manufacturer 
2. Description of the devices 
3. Compliance of patients 
 
 Surgery 
1. Type of anesthesia 
2. Pre-operative care 
3. Post-operative care 
4. Technical procedure 
5. Compliance of care providers 
 
 Rehabilitation 
1. Number of sessions 
2. Timing of sessions 
3. Duration of each session 
4. Content of each session 
5. Mode of delivery 
6. Supervision or not of the session 
7. Compliance of patients 
 
Context Percentage of the following data related to the context reported 
1. Location of recruitment 
2. Setting of recruitment 
3. Country where the trial took place   
4. Number of centers 
5. Details of the centers (e.g., name, center resources, center expertise, center 
organization) 
6. Number of patients recruited in each center 
7. Details of care provider (qualification, name, experience, year of practice) 
8. Number of care providers participating 
 Figure 1: Median percentage (interquartile range) of items of components of external 
validity that were reported in selected reports of pharmaceutical and 
nonpharmaceutical treatments for hip and knee osteoarthritis  
 
A) BASELINE ITEMS 
 
p= 0.006                             
Pharmacologic 
treatment  
median, [IQR] 
Device 
median, [IQR] 
Rehabilitation 
median, [IQR] 
Surgery 
median, [IQR] 
50 [40-60] 50 [30-60] 45 [30-60] 30 [30-40] 
 B) INTERVENTION 
 
p < 0.001 
 
Pharmacologic 
treatment  
median, [IQR] 
Device 
median, [IQR] 
Rehabilitation 
median, [IQR] 
Surgery 
median, [IQR] 
80 [80-100] 33 [33-67] 86 [71-100] 40 [20-40] 
 
 
C) CONTEXT ITEMS 
 
p=0.016 
 
Pharmacologic 
treatment  
median, [IQR] 
Device 
median, [IQR] 
Rehabilitation 
median, [IQR] 
Surgery 
median, [IQR] 
12 [12-25] 31 [12-50] 37 [12-62] 25 [12-25] 
 
PT: pharmacologic treatment;  
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Table 1: Characteristics of selected reports of trials of pharmacologic and nonpharmacologic treatments for hip and knee osteoarthritis. 
 
All 
Treatment 
N (%) 
N=120 
Pharmacologic  
treatment  
N (%) 
N=30 
Non implantable  
devices 
N (%) 
N=30 
Rehabilitation 
 
N (%) 
N=30 
Surgery 
 
N (%) 
N=30 
Type of journal  
     
− General medical journal with high 
impact factor 
13 (11) 4 (13) 4 (13) 4(13) 1 (3) 
− Special medical journal and general 
medical journal with low impact 
factor 
107 (89) 26 (87) 26 (87) 26 (87) 29 (97) 
Medical area 
     
− Hip OA 
18 (15) 1 (3) 1 (3) 5 (17) 11 (37) 
− Knee OA 
90 (75) 23 (77) 27 (90) 21 (70) 19 (63) 
− Hip and knee OA 
12 (10) 6 (20) 2 (7) 4 (13) 0 
Funding 
     
− Public 
45 (38) 6 (20) 15 (50) 17 (57) 7 (23) 
− Manufacturer  
18 (15) 8 (27) 4 (13) 0 6 (20) 
− Public and manufacturer  
7 (6) 2 (7) 0 2 (7) 3 (10) 
− No funding 
8 (7) 2 (7) 0 0 6 (20) 
− Not reported 
42 (35) 12 (40) 11 (37) 11 (37) 8 (27) 
Sample size median  
(IQR
1
) 
100.0  
(60-216) 
213.5 
 (85-431) 
66  
(38-128) 
107  
(77-140) 
95.5  
(52-180) 
Control group 
     
− Placebo intervention 
43 (36) 18 (60) 17 (57) 6 (20) 2 (7) 
− Active treatment  
63 (52) 12 (40) 12 (40) 11 (37) 28 (93) 
− Usual care  
14 (12) 0 1 (3) 13 (43) 0 
Internal validity: adequate      
− Generation of allocation sequences  
61 (51) 19 (63) 11 (37) 18 (60) 13 (43) 
− Allocation concealment 
49 (41) 16 (53) 12 (40) 14 (47) 7 (23) 
− Blinding of patients 
52 (43) 26 (87) 16 (53) 2 (7) 8 (27) 
                                               
1
 IQR: interquartile range 
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− Blinding of  care providers 
38 (32) 24 (80) 11 (37) 2 (7) 1 (3) 
− Blinding of outcome assessors 
71 (59) 25 (83) 22 (73) 11 (37) 13 (43) 
− Intent-to-treat analyses 
38 (32) 10 (33) 10 (33) 12 (40) 6 (20) 
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Table 2: Number (%) of selected reports of trials of pharmaceutical and nonpharmaceutical treatments for hip and knee osteoarthritis that 
described items related to external validity  
Reporting of All treatment 
N (%) 
N=120 
Pharmacologic 
treatment  
N (%) 
N=30 
Devices 
N (%) 
N=30 
Rehabilitation 
N (%) 
N=30 
Surgery 
N (%) 
N=30 
Recruitment 
     
− Method of  recruitment  
43 (36) 8 (27) 13 (43) 18 (60) 4 (13) 
− Specific method to enrich patient’s recruitment 
23 (19) 18 (60) 5 (17) 0 0 
− Duration of recruitment (10 patients/month) 
56 (47) 10 (33) 11 (37) 15 (50) 20 (67) 
Patients 
     
− Inclusion criteria  
118 (98) 30 (100) 30 (100) 30 (100) 28 (93) 
− Exclusion criteria 
106 (88) 30 (100) 27 (90) 28 (93) 21 (70) 
− Rate of strongly justified exclusion criteria in each 
article mean (SD) 
75.5 (23.6) 77.7 (20.7) 79.0 (21.3) 66.9 (26.1) 79.3 (25.6) 
− Rate of potentially justified in each article mean (SD) 
1.5 (4.7) 1.1 (3.4) 1.5 (4.7) 2.8 (6.8) 0.5 (2.3) 
− Rate of poorly justified in each article mean (SD) 
22.9 (23.0) 21.3 (20.5) 19.5 (19.4) 30.3 (26.3) 20.2 (25.3) 
− Flow diagram 
48 (40) 18 (60) 11 (37) 17 (57) 2 (7) 
− Number of eligible patients  
50 (42) 12 (40) 14 (47) 21 (70) 3 (10) 
− Number of patients not meeting inclusion criteria  
39 (33) 9 (30) 8 (27) 19 (63) 3 (10) 
− Number of patients refusing participation  
31 (26) 6 (20) 8 (27) 14 (47) 3 (10) 
− Baseline characteristics of randomized patients  
109 (91) 28 (93) 28 (93) 27 (90) 26 (87) 
   - Age 108 (90) 28 (93) 28 (93) 27 (90) 25 (83) 
   - Sex 101 (84) 27 (90) 24 (80) 25 (83) 25 (83) 
   - Weight/body mass index 74 (62) 22 (73) 18 (60) 17 (57) 17 (57) 
   - Ethnicity 18 (15) 8 (27) 3 (10) 5 (17) 2 (7) 
   - Duration of disease 47 (39) 13 (43) 20 (67) 9 (3 0) 5 (17) 
   - Measure of function status  55 (46) 17 (57) 15 (50) 16 (53) 7 (23) 
   - Level of pain 47 (39) 14 (47) 15 (50) 15 (50) 3 (10) 
   - Description of radiographic damage 27 (23) 5 (17) 11 (37) 4 (13) 7 (23) 
   - NSAIDs/other drugs 19 (16) 6 (20) 6 (20) 6 (20) 1 (3) 
   - Coexisting diseases 14 (12) 2 (7) 1 (3) 9 (30) 2 (7) 
Setting/center/care provider 
     
− Location of recruitment 
46 (38) 9 (30) 17 (57) 17 (57) 3 (10) 
− Setting of recruitment 
40 (33) 7 (23) 16 (53) 16 (53) 1 (3) 
− Country where the trial took place   
25 (21) 8 (27) 6 (20) 10 (33) 1 (3) 
− Number of centers 
54 (45) 19 (63) 16 (53) 15 (50) 4 (13) 
− Details of the centers  
24 (20) 3 (10) 10 (33) 9 (30) 2 (7) 
− Number of patients recruited in each center 
0 0 0 0 0 
− Details of care provider  
35 (29) 2 (7) 6 (20) 10 (33) 17 (57) 
 30 
− Number of care providers  
33 (28) 2 (7) 4 (13) 7 (23) 20 (67) 
 31/03/2009 
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Table 3: Number (%) of selected reports of trials of pharmaceutical and nonpharmaceutical 
treatments for hip and knee osteoarthritis that described the intervention 
 
  
Reports Reporting of N (%) 
Mode of administration 30 (100) 
Dosage  30 (100) 
Duration of treatment 30 (100) 
Frequency of treatment 30 (100) 
Pharmacologic 
Treatment  
(N=30) 
 
Compliance of patients 10 (33) 
 
  
Type of anesthesia 4 (13) 
Pre-operative care 2 (7) 
Post-operative care 15 (50) 
Technical procedure 30 (100) 
Surgery 
(N=30) 
 
Compliance of care providers 0 
 
  
Number of sessions 29 (97) 
Timing of sessions 26 (87) 
Duration of each session 24 (80) 
Content of each session 28 (93) 
Mode of delivery 
Supervision or not 
27 (90) 
25 (83) 
Compliance of patients 15 (50) 
Rehabilitation 
(N=30) 
 
  
 
  
Manufacturer 9 (30) 
Description of the device 28 (93) 
Devices 
(N=30) 
 
Compliance of patients 9 (30) 
 
 
 
 
 
